放射性复发前列腺癌的局部挽救性高强度聚焦超声治疗
回顾性注册分析纳入2006年11月至2015年8月接受局部挽救性高强度聚焦超声(FS-HIFU)的150例放射性复发前列腺癌患者,中位随访35个月;复合失败率61%、生化失败率51.3%,3年复合无事件生存率40%、生化无病生存率48%,并发症发生率较低。
要点
- FS-HIFU后复合失败91/150(61%),生化失败77/150(51.3%)。
- 3年复合无事件生存率40%(95%CI 31-50),生化无病生存率48%(95%CI 39-59)。
- 并发症包括尿路感染11.3%(17/150)、膀胱颈狭窄8%(12/150)、直肠尿道瘘2%(3/150)、耻骨骨炎0.7%(1/150)。
核心结论
- 局部挽救性HIFU并发症和副作用发生率相对较低,短至中期复合无事件生存率和生化控制尚可,尤其在该相对高危队列中,但仍低于当前全腺体挽救治疗。
- 作者认为局部挽救治疗可能为高危男性提供疾病控制,同时尽量减少额外治疗并发症。
研究设计与样本
- 回顾性注册分析,纳入150例2006年11月至2015年8月接受局部挽救性高强度聚焦超声(Sonablate 500)的放射性复发前列腺癌患者。
- 通过盆腔MRI淋巴结评估、放射性核素骨扫描和正电子发射断层扫描(PET)成像(18F-氟代脱氧葡萄糖胆碱PET或胆碱PET-CT)排除转移性疾病。
- 本研究中心当前临床实践要求通过胆碱PET和骨扫描两者排除转移性疾病。
- 采用多参数MRI(T2加权、弥散加权和动态对比增强成像)联合系统或模板前列腺定位活检进行癌症定位。
- 主要结局为复合失败,包括生化失败和/或局部或远处影像学阳性结果和/或活检阳性和/或全身治疗和/或转移/前列腺癌特异性死亡;次要结局为采用Phoenix-ASTRO定义(前列腺特异性抗原[PSA]最低值+2 ng/mL)的生化失败。
主要发现
- 局部挽救性HIFU时平均(标准差)年龄69.8(6.1)岁,局部挽救性HIFU前中位(四分位距)PSA为5.5(3.6-7.9)ng/mL,中位(四分位距)随访35(22-52)个月。
- 根据D'Amico分类,局部挽救性HIFU前低危2.7%(4/150)、中危39.3%(59/150)、高危41.3%(62/150)。
- 复合失败发生于61%(91/150)的患者,生化失败发生于51.3%(77/150)。
- 整个队列3年Kaplan-Meier复合无事件生存率为40%(95%CI 31-50);局部挽救性HIFU前低、中、高危组3年复合无事件生存率分别为100%、49%和24%。
- 整个队列3年Kaplan-Meier生化无病生存率为48%(95%CI 39-59);局部挽救性HIFU前低、中、高危组3年生化无病生存率分别为100%、61%和32%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess short- to medium-term cancer control rates and side effects of focal salvage high- intensity focused ultrasound (HIFU). MATERIALS AND METHODS: A retrospective registry analysis identified 150 men who underwent focal salvage HIFU (FS-HIFU) (Sonablate 500) between November 2006 and August 2015. Metastatic disease was excluded by nodal assessment on the pelvic MRI, a radioisotope bone scan and positron-emission tomography (PET) imaging (choline-18F-fluorodeoxyglucose PET or choline PET-CT). In our current clinical practice, metastatic disease must be excluded by both choline PET and bone scan. Localization of cancer was carried out using multiparametric MRI of the prostate (T2-weighted, diffusion-weighted and dynamic contrast-enhanced imaging) with systematic or template prostate mapping biopsies. The primary outcome was a composite failure incorporating biochemical failure (BCF) and/or positive localized or distant imaging results and/or positive biopsy and/or systemic therapy and/or metastases/prostate cancer-specific death. The secondary outcome was BCF using the Phoenix-ASTRO definition (prostate-specific antigen [PSA] nadir + 2 ng/mL). We used Kaplan-Meier analysis and Cox proportional hazards regression to quantify the effect of the determinants on the endpoints. RESULTS: The mean (standard deviation [sd]) patient age at focal salvage HIFU was 69.8 (6.1) years and the median (interquartile range [IQR]) PSA pre-focal salvage HIFU was 5.5 (3.6-7.9) ng/mL. The median (IQR) follow-up was 35 (22-52) months. Patients were classified as having low- 2.7% (4/150), intermediate- 39.3% (59/150) and high-risk disease 41.3% (62/150) according to D'Amico classification, prior to focal salvage HIFU. Composite failure occurred in 61% of patients (91/150) and BCF occurred in 51.3% (77/150). The Kaplan-Meier composite endpoint-free survival (CEFS) rate at 3 years was 40% (95% confidence interval [CI] 31-50) for the entire group. Kaplan-Meier estimates of CEFS were 100%, 49% and 24% at 3 years in the low-, intermediate- and high-risk groups pre-salvage HIFU, respectively. The Kaplan-Meier biochemical disease-free survival (BDFS) rate at 3 years was 48% (95% CI 39-59) for the entire group. Kaplan-Meier estimates of BDFS were 100%, 61% and 32% at 3 years in the low-, intermediate- and high-risk groups pre-salvage HIFU, respectively. Complications included urinary tract infection (11.3%; 17/150), bladder neck stricture (8%; 12/150), recto-urethral fistula after one HIFU procedure (2%; 3/150) and osteitis pubis (0.7%; 1/150). CONCLUSION: Focal salvage HIFU conferred a relatively low complication and side effect rate. CEFS and biochemical control in the short to medium term were reasonable, especially in this relatively high-risk cohort, but still low compared with current whole-gland salvage therapies. Focal salvage therapy may offer disease control in men at high risk whilst minimizing additional treatment morbidities.
引用
- Kanthabalan A, Peters M, Van Vulpen M, et al. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. BJU Int. 2017. PMID: 28258616. doi:10.1111/bju.13831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。